Across four African nations, a generation of young people living with HIV has demonstrated that the form medicine takes can matter as much as the medicine itself. A UCL-led trial found that eight-weekly injections suppressed the virus far more reliably than daily tablets in adolescents — a population long known to struggle with the quiet, relentless discipline of daily treatment. The results arrive as a kind of proof that better tools exist, even as the systems meant to deliver them remain out of reach for the very communities that need them most.
Eight-weekly HIV injections outperform daily tablets in young people, UCL trial shows
1.6 million adolescents aged 10-19 live with HIV globally; improved treatment adherence through injections could reduce transmission and improve long-term health outcomes for this vulnerable population.
Nine out of ten adolescents with HIV live in Africa. Yet the treatment is not accessible to them.
Mark
So the injections work better than the pills for keeping the virus suppressed. What's the actual difference in numbers?
Mimi
Over two years, only one percent of adolescents on injections had their virus rebound—that's two young people out of the group. On daily pills, it was six percent, or 15 adolescents. That's a meaningful gap.
Luke
But we should be careful here. Both groups started with fully suppressed virus and no history of treatment failure. These are already the most adherent patients. The question is whether the injections help because they're easier, or because something about the drug formulation itself is superior.
Mimi
That's fair. The researchers do point out that nearly all the adolescents—94 percent—said the injections were much easier than daily pills. So adherence and preference are clearly part of the story.
Mark
Why does this matter more for adolescents than for adults?
Mimi
Adults on injectables in earlier trials showed no advantage over pills—they were just as good. But adolescents are dealing with school, peers, stigma. Taking a pill every day is a constant reminder of their status. An injection every eight weeks lets them live more normally.
Luke
The source says adolescents have "historically done worse" on antiretrovirals than adults. But it doesn't explain why. Is it purely adherence, or are there biological differences, or social factors we're not seeing?
Mimi
The trial doesn't isolate those causes. What it shows is the outcome: when you remove the daily pill burden, adolescents do better.
Mark
And this is happening in Africa, where most adolescents with HIV actually live.
Mimi
Right. Nine out of ten adolescents with HIV globally live in Africa. But the injectable treatment isn't available there yet.
Luke
What's the actual barrier? Cost, or something else?
Mimi
All of it. The drugs are still patented, so they're expensive. Rilpivirine needs refrigeration. You need trained nurses to give the injections every eight weeks. And there's no generic version yet.
Mark
So even though the trial proves it works better, the people who need it most can't get it.
Luke
That's the gap. And it may widen if newer injectables that only need dosing twice a year enter the market—they'll face the same access problems.
El Pulso
- Only 1% of adolescents on eight-weekly injections experienced viral rebound over nearly two years, compared to 6% on daily tablets — a gap that signals not just a clinical difference but a structural one in how young people can realistically manage a lifelong condition.
- 94% of adolescents in the injectable group said the regimen was substantially easier, pointing to how deeply the burden of daily, visible medication shapes the lives of young people navigating stigma, school, and social belonging.
- The 476 adolescents enrolled across Kenya, South Africa, Uganda, and Zimbabwe represent a population where nine in ten of the world's adolescent HIV cases occur — yet the injectable treatment they tested remains largely unavailable to them outside the trial itself.
- Patents, refrigeration demands, and the need for trained nursing staff every eight weeks create a layered access problem that a stronger WHO recommendation alone cannot resolve.
- Next-generation injectables requiring only twice-yearly dosing are already in development — but researchers warn they will likely face the same access barriers, threatening to widen the gap between what medicine can do and what it actually delivers in low-resource settings.
Across four African nations, a generation of young people living with HIV has demonstrated that the form medicine takes can matter as much as the medicine itself. A UCL-led trial found that eight-weekly injections suppressed the virus far more reliably than daily tablets in adolescents — a population long known to struggle with the quiet, relentless discipline of daily treatment. The results arrive as a kind of proof that better tools exist, even as the systems meant to deliver them remain out of reach for the very communities that need them most.
A trial led by University College London and conducted across Kenya, South Africa, Uganda, and Zimbabwe has found that adolescents with HIV do significantly better on injections given every eight weeks than on the daily tablets that remain standard care. Of the 476 young people aged 12 to 19 enrolled in the study, just one percent of those receiving the injectable combination — two individuals — experienced viral rebound over nearly two years of follow-up. Among those taking daily pills, six percent saw their viral loads rise. The results, published in The Lancet, mark a meaningful departure from earlier adult trials, where injectables proved merely equivalent to tablets. In adolescents, they outperform them.
The injectable regimen combines cabotegravir and rilpivirine, administered by a nurse every eight weeks. Nearly all adolescents in that group — 94 percent — found it substantially easier than managing a daily pill. That preference carries clinical weight. Adolescents living with HIV have historically struggled with adherence more than adults, facing the daily task of taking medication while navigating school, social life, and the stigma that still surrounds the disease. Shifting to bimonthly injections removes a constant, visible reminder of their status and eliminates the risk of being seen taking medication by peers.
About 1.6 million adolescents worldwide live with HIV, and nine in ten of them are in Africa. Yet the injectable treatment remains largely inaccessible across the continent outside a handful of clinics. In the United States and Europe, adolescents aged 12 and older can already be prescribed these injectables — but the same access does not exist where the burden of disease is greatest.
Several obstacles block wider adoption. The drugs remain under patent, making them far more expensive than generic daily tablets. Rilpivirine requires refrigeration throughout its supply chain — a significant challenge in settings with limited cold storage. And administering injections requires trained nursing staff available every eight weeks, a more intensive demand than the quarterly or biannual clinic visits typical for adolescents on tablets. No agreement yet exists on whether generic versions will be developed.
The trial's corresponding author, Dr. Deborah Ford, warned that the access gap risks deepening inequalities in HIV care across Africa. Second- and third-generation injectables — some requiring dosing only twice a year — are already in development, but are expected to face the same barriers. The WHO currently lists injectable antiretrovirals as an alternative option for people with fully suppressed virus, and the LATA findings may prompt a stronger recommendation. But as trial physician Dr. Mutsa Bwakura-Dangarembizi put it plainly: the injections work better, adolescents prefer them, and they are well tolerated — and they are not available where they are needed most.
A trial conducted across four African countries has found that adolescents with HIV fare significantly better on injections administered every eight weeks than on the daily tablets that remain standard care. Researchers from University College London led the study, which tested the approach in Kenya, South Africa, Uganda, and Zimbabwe, enrolling 476 young people aged 12 to 19 who had been stable on tablet treatment for at least a year. The results, published in The Lancet, show a stark difference in outcomes: after nearly two years of follow-up, only one percent of adolescents receiving the injectable formulation—two young people—experienced confirmed viral rebound, the dangerous moment when the amount of virus in the bloodstream begins to rise again. By contrast, six percent of those taking daily pills, or 15 adolescents, saw their viral loads increase.
The injectable treatment combines two drugs, cabotegravir and rilpivirine, administered by a nurse every eight weeks. Nearly all of the young people in that group—94 percent—reported that the injections were substantially easier than managing a daily pill regimen. This matters more than convenience alone. Adolescents living with HIV have historically struggled with adherence to antiretroviral therapy compared to adults, facing the daily burden of taking medication while navigating school, social life, and the stigma that still surrounds the disease. The ability to shift from daily pills to bimonthly injections removes a constant, visible reminder of their status and eliminates the risk of being seen taking medication in front of peers.
About 1.6 million adolescents worldwide, aged 10 to 19, live with HIV. Nine out of ten of them live in Africa. Yet the injectable treatment is not currently available to them. In the United States and Europe, adolescents aged 12 and older can be prescribed these injectables, along with adults, but across Africa the treatment remains largely inaccessible outside a handful of clinics. Professor Sarah Pett, the chief investigator of the trial, called the results stronger than what researchers have seen in adult populations. Earlier trials in adults showed that injectables were simply as effective as tablets—no better, no worse. The finding in adolescents is different: the injections actually outperform the pills.
Several practical obstacles stand in the way of wider adoption in lower-income settings. The injectable drugs remain under patent, making them substantially more expensive to produce and purchase than generic daily tablets. Rilpivirine requires refrigeration throughout its supply chain and storage, a challenge in settings where cold storage infrastructure is limited. Administering the injections requires trained nursing staff available every eight weeks, whereas adolescents on tablets might visit a clinic only every three to six months. There is no agreement yet on whether generic versions of the injectable treatment will be developed and made available.
Dr. Deborah Ford, corresponding author on the study, warned that the gap in access threatens to deepen inequalities in HIV care across the continent. Second- and third-generation injectables are already being tested in trials that would require dosing only twice a year—treatments that will likely face the same access barriers. The World Health Organization currently lists injectable antiretrovirals as an "alternative" option for people whose virus is fully suppressed and who do not have active hepatitis B. The LATA trial findings may prompt the organization to strengthen that recommendation, but a stronger recommendation alone will not solve the problem of availability. Dr. Mutsa Bwakura-Dangarembizi, a trial physician based in Harare, Zimbabwe, captured the tension plainly: the injections work better, adolescents prefer them, and they are well tolerated—but they are not available where they are needed most. The trial was funded by the European Union and Johnson & Johnson Innovative Medicines, which supplied the drugs themselves, raising questions about how access will be negotiated in the years ahead.
Citas Notables
The benefits of this form of treatment for adolescents is stronger than we have seen for adults. Previous trials in adults have shown only that injectables are no less effective than tablets.— Professor Sarah Pett, UCL Innovative Clinical Trials Unit
The lack of availability of injectable treatments in Africa risks increasing inequalities in HIV care, leaving most people living with HIV without access to treatments that are available in high-income settings.— Dr. Deborah Ford, UCL Innovative Clinical Trials Unit
Quieres la nota completa?
Lee el original en News-Medical ↗
Health & Medicine